Sam Brusco, Associate Editor03.27.24
Olympus Corporation of the Americas is partnering with the American Lung Association to educate lung cancer patients about the care pathway to diagnose and stage lung nodules.
The Olympus-sponsored lung nodules educational materials help patients understand diagnosis and staging, and why it’s important to their treatment journey. The company said the information will empower patients to make the best-informed decisions regarding their care.
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a procedure pioneered by Olympus. The company said it’s helped create a foundation for targeted cancer treatment like immunotherapy. The tech helps locate nodules and lymph nodes, then collect tissue sampled needed for diagnosis and staging. The analysis informs personalized, targeted cancer therapy.
Tech like EBUS-TBNA can help physicians tell how far the lung cancer has spread and understand the cancer cells’ genetic makeup. Olympus said it’s proud to sponsor the new Lung.org patient education campaign aimed at helping people get the care that they need in order to be diagnosed and treated as early as possible.
“Olympus is very excited to support this great new educational resource for lung cancer patients through our partnership with the American Lung Association,” said Jovan Reyerson, senior VP of Medical and Scientific Affairs at Olympus Corporation of the Americas. “Empowered patients are able to more actively participate in their care, ask relevant questions, and advocate for themselves.”
Olympus advised that potential complications associated with endoscopic ultrasound (EUS) include sore throat, infection, bleeding, perforation, and/or tumor seeding (when EUS-fine needle aspiration or biopsy is performed).
Earlier this month, Olympus rescinded the purchase of Korea-based gastrointestinal device maker Taewoong Medical.
The Olympus-sponsored lung nodules educational materials help patients understand diagnosis and staging, and why it’s important to their treatment journey. The company said the information will empower patients to make the best-informed decisions regarding their care.
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a procedure pioneered by Olympus. The company said it’s helped create a foundation for targeted cancer treatment like immunotherapy. The tech helps locate nodules and lymph nodes, then collect tissue sampled needed for diagnosis and staging. The analysis informs personalized, targeted cancer therapy.
Tech like EBUS-TBNA can help physicians tell how far the lung cancer has spread and understand the cancer cells’ genetic makeup. Olympus said it’s proud to sponsor the new Lung.org patient education campaign aimed at helping people get the care that they need in order to be diagnosed and treated as early as possible.
“Olympus is very excited to support this great new educational resource for lung cancer patients through our partnership with the American Lung Association,” said Jovan Reyerson, senior VP of Medical and Scientific Affairs at Olympus Corporation of the Americas. “Empowered patients are able to more actively participate in their care, ask relevant questions, and advocate for themselves.”
Olympus advised that potential complications associated with endoscopic ultrasound (EUS) include sore throat, infection, bleeding, perforation, and/or tumor seeding (when EUS-fine needle aspiration or biopsy is performed).
Earlier this month, Olympus rescinded the purchase of Korea-based gastrointestinal device maker Taewoong Medical.